Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/13728
|
| Title: | Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells |
| Authors: | Yang, WB;Wu, AC;Hsu, TI;Liou, JP;Lo, WL;Chang, KY;Chen, PY;Kikkawa, U;Yang, ST;Kao, TJ;Chen, RM;Chang, WC;Ko, CY;Chuang, JY |
| Contributors: | National Institute of Cancer Research |
| Abstract: | DNA repair promotes the progression and recurrence of glioblastoma (GBM). However, there remain no effective therapies for targeting the DNA damage response and repair (DDR) pathway in the clinical setting. Thus, we aimed to conduct a comprehensive analysis of DDR genes in GBM specimens to understand the molecular mechanisms underlying treatment resistance. Herein, transcriptomic analysis of 177 well-defined DDR genes was performed with normal and GBM specimens (n = 137) from The Cancer Genome Atlas and further integrated with the expression profiling of histone deacetylase 6 (HDAC6) inhibition in temozolomide (TMZ)-resistant GBM cells and patient-derived tumor cells. The effects of HDAC6 inhibition on DDR signaling were examined both in vitro and intracranial mouse models. We found that the expression of DDR genes, involved in repair pathways for DNA double-strand breaks, was upregulated in highly malignant primary and recurrent brain tumors, and their expression was related to abnormal clinical features. However, a potent HDAC6 inhibitor, MPT0B291, attenuated the expression of these genes, including RAD51 and CHEK1, and was more effective in blocking homologous recombination repair in GBM cells. Interestingly, it resulted in lower cytotoxicity in primary glial cells than other HDAC6 inhibitors. MPT0B291 reduced the growth of both TMZ-sensitive and TMZ-resistant tumor cells and prolonged survival in mouse models of GBM. We verified that HDAC6 regulated DDR genes by affecting Sp1 expression, which abolished MPT0B291-induced DNA damage. Our findings uncover a regulatory network among HDAC6, Sp1, and DDR genes for drug resistance and survival of GBM cells. Furthermore, MPT0B291 may serve as a potential lead compound for GBM therapy. |
| Date: | 2021-09-28 |
| Relation: | Cell Death and Disease. 2021 Sep 28;12(10):Article number 884. |
| Link to: | http://dx.doi.org/10.1038/s41419-021-04182-w |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2041-4889&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000701145700002 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85115884774 |
| Appears in Collections: | [張光裕] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB34584069.pdf | | 6667Kb | Adobe PDF | 267 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
